lacosamide (Vimpat, erlosamide, harkoseride)
Jump to navigation
Jump to search
Indications
- partial seizures in adults & in children 4 years & older
- primary generalized tonic-clonic seizures n adults & in children 4 years & older[3]
Contraindications
- avoid in patients with severe liver failure[2]
Dosage
- oral solution or tablet (children)
- injection (adults only)
Dosage adjustment in renal failure
Pharmacokinetics
- combined hepatic/renal elimination[2]
Adverse effects
- common
- serious
- other
Drug interactions
- increased incidence of dizziness when used with
- drug interaction(s) anticonvulsants with anti-bacterial agents
- drug interaction(s) anticonvulsants with statins
Mechanism of action
- blocks sodium channels
Notes
Manufacturer: UCB
More general terms
References
- ↑ Prescriber's Letter 16(2): 2009 New Drugs Approved by the FDA in 2008 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250213&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Jump up to: 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 18 American College of Physicians, Philadelphia 2012, 2015, 2018
- ↑ Jump up to: 3.0 3.1 George J Your Brain on Cocoa; MS-Gut Link; Autism and Newborn Hearing
News and commentary from the world of neurology and neuroscience. MedPage Today November 24, 2020 https://www.medpagetoday.com/neurology/generalneurology/89868
UCB Press Release. November 17, 2020 UCB-w VIMPAT <TM> (lacosamide) CV now approved by FDA in U.S. for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy. https://www.ucb.com/stories-media/Press-Releases/article/UCB-s-VIMPAT-lacosamide-CV-now-approved-by-FDA-in-U-S-for-primary-generalized-tonic-clonic-seizures-and-expanded-pediatric-use-for-people-living-with-epilepsy